BioSpace News Archive

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced its Elecsys® Anti-SARS-CoV-2 antibody test is live at more than 20 commercial and hospital lab sites throughout the United States, with plans in the next several weeks to increase to more than 200 commercial and hospital lab sites with the ability to perform millions of tests per week.

Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, today announced that it will hold an introductory conference call for its shareholders.

Ocular Therapeutix™, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that it has commenced an underwritten public offering of its common stock.

ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced today the closing of its initial public offering of 14,082,475 shares

American Skin Association has announced the recipients of the 2020 David Martin Carter Mentor Award and the 2020 Research Achievement Awards.

The U.S. Food and Drug Administration continued to take action in the ongoing response effort to the COVID-19 pandemic

Protech Home Medical Corp. (“Protech” or the “Company”) (TSXV: PTQ), a healthcare services company with operations in the U.S., today announced its second quarter fiscal 2020 financial results and operational highlights for the period ended March 31, 2020.

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2020.

G Medical Innovations Holdings Ltd is pleased to report a significant development for the Company with receipt of Emergency Use Authorisation status from the US FDA for the Company’s Vital Signs Monitoring System ECG Patch for the remote monitoring of the QT interval of an ECG in patients who are undergoing treatment in a hospital setting for COVID-19 with drugs that can prolong QT intervals and may cause fatal arrhythmias.

SOMAVAC® Medical Solutions, Inc. today announced the commercial launch of the SOMAVAC® SVS and a partnership with A Fitting Place.